https://www.selleckchem.com/pr....oducts/pyrintegrin.h
ients with sarcoidosis needed glaucoma surgery, and vitrectomy was required in 50% for vitreous opacity caused by ML or sarcoidosis. This review summarizes published findings concerning the Baerveldt-350 glaucoma drainage device (GDD). Most studies focus on the comparison between different treatments; in this review, the primary focus is efficacy, safety, and place in therapy for the Baerveldt implant. A systematic review was performed using the PubMed database for literature on March 13th, 2020. Efficacy was estimated by performing
Like
Comment
Share
